MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-10.74%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$582M
AUM Growth
+$582M
(-17%)
Cap. Flow
-$7.77M
Cap. Flow
% of AUM
-1.34%
Top 10 Holdings %
Top 10 Hldgs %
47.58%
Holding
53
New
6
Increased
26
Reduced
8
Closed
10
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$33.3M |
| 2 |
ARS Pharmaceuticals
SPRY
|
$16.5M |
| 3 |
Alkermes
ALKS
|
$11.1M |
| 4 |
United Therapeutics
UTHR
|
$11.1M |
| 5 |
Janux Therapeutics
JANX
|
$9.1M |
Top Sells
| 1 |
Insmed
INSM
|
$26.9M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
$24.4M |
| 3 |
Disc Medicine
IRON
|
$22M |
| 4 |
Scholar Rock
SRRK
|
$18M |
| 5 |
Akero Therapeutics
AKRO
|
$12.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $57.9M | 9.95% | 7,648,268 | – | – |
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $33.3M | 5.72% | +100,415 | New | +$33.3M |
|
3
Zai Lab
ZLAB
$3.68B
| $30.1M | 5.18% | 833,659 +33,659 | +4% | +$1.22M |
|
4
Edgewise Therapeutics
EWTX
$1.51B
| $24.3M | 4.18% | 1,105,444 +26,128 | +2% | +$575K |
|
5
Lantheus
LNTH
$3.73B
| $22.7M | 3.9% | 232,387 -3,826 | -2% | -$373K |
|
6
PTC Therapeutics
PTCT
$3.92B
| $22.4M | 3.85% | 439,977 +5,210 | +1% | +$266K |
|
7
Natera
NTRA
$23.1B
| $22.2M | 3.82% | 157,047 -3,579 | -2% | -$506K |
|
8
Trevi Therapeutics
TRVI
$883M
| $21.6M | 3.71% | 3,428,366 +333,470 | +11% | +$2.1M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $21.2M | 3.64% | 631,964 +14,929 | +2% | +$501K |
|
10
Avidity Biosciences
RNA
$5.99B
| $21.1M | 3.62% | 714,224 +11,243 | +2% | +$332K |
|
11
Guardant Health
GH
$8.41B
| $18.9M | 3.24% | 442,656 -10,083 | -2% | -$430K |
|
|
12
United Therapeutics
UTHR
$13.8B
| $18.2M | 3.12% | 58,907 +35,907 | +156% | +$11.1M |
|
|
13
ARS Pharmaceuticals
SPRY
$1.15B
| $16.5M | 2.84% | +1,313,104 | New | +$16.5M |
|
14
Compass Therapeutics
CMPX
$483M
| $16M | 2.76% | 8,442,783 -125,113 | -1% | -$238K |
|
|
15
Janux Therapeutics
JANX
$1.37B
| $15.3M | 2.63% | 567,193 +337,193 | +147% | +$9.1M |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $14.4M | 2.48% | 398,445 +7,427 | +2% | +$269K |
|
17
MoonLake Immunotherapeutics
MLTX
$3.54B
| $12.3M | 2.12% | 316,049 +819 | +0.3% | +$32K |
|
18
Wave Life Sciences
WVE
$1.53B
| $12.2M | 2.1% | 1,509,580 +20,343 | +1% | +$164K |
|
19
Revolution Medicines
RVMD
$7.1B
| $11.2M | 1.93% | 317,083 +3,266 | +1% | +$115K |
|
|
20
Alkermes
ALKS
$4.78B
| $11.1M | 1.92% | +337,603 | New | +$11.1M |
|
21
Olema Pharmaceuticals
OLMA
$375M
| $11M | 1.89% | 2,930,446 +17,896 | +0.6% | +$67.3K |
|
22
Rocket Pharmaceuticals
RCKT
$354M
| $10.8M | 1.86% | 1,618,265 +597,706 | +59% | +$3.99M |
|
23
iTeos Therapeutics
ITOS
| $10.4M | 1.79% | 1,745,943 | – | – |
|
24
Cartesian Therapeutics
RNAC
$261M
| $10.4M | 1.79% | 790,779 +69,640 | +10% | +$918K |
|
25
Twist Bioscience
TWST
$1.63B
| $10.3M | 1.76% | 261,215 -6,282 | -2% | -$247K |
|